{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:39:03Z","timestamp":1787063943506,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,18]]},"DOI":"10.7759\/cureus.86275","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:13:52Z","timestamp":1750234432000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case Report on Pericardial Effusion Associated With Selpercatinib in the First Patient With Rearranged During Transfection (RET) Fusion-Positive Lung Cancer"],"prefix":"10.7759","author":[{"given":"Tomoko","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Isoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Jotatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yatera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, RET, by DNA rearrangement","volume":"42","author":"Takahashi M","year":"1985","unstructured":"Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell. 1985, 42:581-8. 10.1016\/0092-8674(85)90115-1","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon A","year":"2018","unstructured":"Drilon A, Hu ZI, Lai GG, Tan DS. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018, 15:151-67. 10.1038\/nrclinonc.2017.175","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi K","year":"2012","unstructured":"Takeuchi K, Soda M, Togashi Y, et al.. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012, 18:378-81. 10.1038\/nm.2658","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno T","year":"2012","unstructured":"Kohno T, Ichikawa H, Totoki Y, et al.. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012, 18:375-7. 10.1038\/nm.2644","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson D","year":"2012","unstructured":"Lipson D, Capelletti M, Yelensky R, et al.. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012, 18:382-4. 10.1038\/nm.2673","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li AY","year":"2019","unstructured":"Li AY, McCusker MG, Russo A, et al.. RET fusions in solid tumors. Cancer Treat Rev. 2019, 81:101911. 10.1016\/j.ctrv.2019.101911","journal-title":"Cancer Treat Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.188","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon A","year":"2018","unstructured":"Drilon A, Hu ZI, Lai GG, Tan DS. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018, 15:150. 10.1038\/nrclinonc.2017.188","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon A","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DS, et al.. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020, 383:813-24. 10.1056\/NEJMoa2005653","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou C","year":"2023","unstructured":"Zhou C, Solomon B, Loong HH, et al.. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023, 389:1839-50. 10.1056\/NEJMoa2309457","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02076","article-title":"Selpercatinib in RET fusion-positive non-small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II trial","volume":"43","author":"Gautschi O","year":"2025","unstructured":"Gautschi O, Park K, Solomon BJ, et al.. Selpercatinib in RET fusion-positive non-small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II trial. J Clin Oncol. 2025, 43:1758-64. 10.1200\/JCO-24-02076","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon A","year":"2023","unstructured":"Drilon A, Subbiah V, Gautschi O, et al.. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial. J Clin Oncol. 2023, 41:385-94. 10.1200\/JCO.22.00393","journal-title":"J Clin Oncol"},{"key":"ref12","unstructured":"U.S. National Library of Medicine. selpercatinib. (2023). Accessed: June 7, 2025: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828.."},{"key":"ref13","unstructured":"Eli Lilly Japan KK. retevmo proper use guide. (2023). Accessed: June 7, 2025: https:\/\/medical.lilly.com\/jp\/answers\/144698."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13250-1","article-title":"Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database","volume":"24","author":"Qian J","year":"2024","unstructured":"Qian J, Zhang S, Jiang C. Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database. BMC Cancer. 2024, 24:1486. 10.1186\/s12885-024-13250-1","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00005.2002","article-title":"Vascular growth factors and lymphangiogenesis","volume":"82","author":"Jussila L","year":"2002","unstructured":"Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002, 82:673-700. 10.1152\/physrev.00005.2002","journal-title":"Physiol Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100792","article-title":"Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)","volume":"6","author":"Reingold RE","year":"2025","unstructured":"Reingold RE, Parisi R, Harada G, et al.. Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292). JTO Clin Res Rep. 2025, 6:100792. 10.1016\/j.jtocrr.2025.100792","journal-title":"JTO Clin Res Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae282","article-title":"Long-term safety of selpercatinib for rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time","volume":"29","author":"Raez LE","year":"2024","unstructured":"Raez LE, Massey AC, Barker SS, Peterson PM, Liming K, Pennell NA. Long-term safety of selpercatinib for rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. Oncologist. 2024, 29:1068-78. 10.1093\/oncolo\/oyae282","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/382082","article-title":"Cytokines in pericardial effusion of patients with inflammatory pericardial disease","volume":"2012","author":"Karatolios K","year":"2012","unstructured":"Karatolios K, Moosdorf R, Maisch B, Pankuweit S. Cytokines in pericardial effusion of patients with inflammatory pericardial disease. Mediators Inflamm. 2012, 2012:382082. 10.1155\/2012\/382082","journal-title":"Mediators Inflamm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201599","article-title":"Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report","volume":"13","author":"Scattolin D","year":"2023","unstructured":"Scattolin D, Scagliori E, Scapinello A, Fantin A, Guarneri V, Pasello G. Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report. Front Oncol. 2023, 13:1201599. 10.3389\/fonc.2023.1201599","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.06.008","article-title":"Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy","volume":"17","author":"Kalchiem-Dekel O","year":"2022","unstructured":"Kalchiem-Dekel O, Falcon CJ, Bestvina CM, et al.. Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. J Thorac Oncol. 2022, 17:1130-6. 10.1016\/j.jtho.2022.06.008","journal-title":"J Thorac Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373547-a-case-report-on-pericardial-effusion-associated-with-selpercatinib-in-the-first-patient-with-rearranged-during-transfection-ret-fusion-positive-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:13:53Z","timestamp":1750234433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373547-a-case-report-on-pericardial-effusion-associated-with-selpercatinib-in-the-first-patient-with-rearranged-during-transfection-ret-fusion-positive-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.86275","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}